U.S. FDA Panel Urges Approval Of Novo Nordisk Injection For Obesity

(RTTNews) - Insulin maker Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee or EMDAC of the United States Food and Drug Administration or FDA has completed its meeting related to the New Drug Application or NDA for Saxenda, the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue to treat obesity.

The panel voted 14 to 1 to recommend the drug, that is already approved for diabetes under the brand name Victoza. If it is approved as an obesity drug by the FDA, it would be marketed under the name Saxenda. The FDA typically follows its advisory panels' recommendations.